Transplantation of bovine adrenocortical cells encapsulated in alginate. by Balyura, Mariya et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1073/pnas.1500242112
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Balyura, M., Gelfgat, E., Ehrhart-Bornstein, M., Ludwig, B., Gendler, Z., Barkai, U., ... Bornstein, S. (2015).
Transplantation of bovine adrenocortical cells encapsulated in alginate. Proceedings of the National Academy of
Sciences of the United States of America, 112(1500242112), 2527–2532. [no.8].
https://doi.org/10.1073/pnas.1500242112
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Jul. 2020
Transplantation of bovine adrenocortical cells
encapsulated in alginate
Mariya Balyuraa,1, Evgeny Gelfgata,1, Monika Ehrhart-Bornsteina,b, Barbara Ludwiga,b, Zohar Gendlerc, Uriel Barkaic,
Baruch Zimermanc, Avi Rotemc, Norman L. Blockd,e,f, Andrew V. Schallyd,e,f,2, and Stefan R. Bornsteina,b,g
aUniversity Hospital Carl Gustav Carus, Department of Medicine III and bCenter for Regenerative Therapies Dresden, Technische Universität Dresden,
01307 Dresden, Germany; cBeta-O2 Technologies, Rosh HaAyin 4809900, Israel; Divisions of dEndocrinology and eHematology–Oncology, Department of Medicine
and Department of Pathology, University of Miami, Miller School of Medicine, Miami, FL 33136; fVeterans Affairs Medical Center, Miami, FL 33125; and gDiabetes
and Nutritional Sciences Division, King’s College London, London SE5 9NU, United Kingdom
Contributed by Andrew V. Schally, January 13, 2015 (sent for review December 8, 2014; reviewed by Christian A. Koch, Constantine A. Stratakis, and
Hubert Vaudry)
Current treatment options for adrenal insufficiency are limited to
corticosteroid replacement therapies. However, hormone therapy
does not replicate circadian rhythms and has unpleasant side
effects especially due to the failure to restore normal function of
the hypothalamic–pituitary–adrenal (HPA) axis. Adrenal cell trans-
plantation and the restoration of HPA axis function would be
a feasible and useful therapeutic strategy for patients with adre-
nal insufficiency. We created a bioartificial adrenal with 3D cell
culture conditions by encapsulation of bovine adrenocortical cells
(BACs) in alginate (enBACs). We found that, compared with BACs
in monolayer culture, encapsulation in alginate significantly in-
creased the life span of BACs. Encapsulation also improved signif-
icantly both the capacity of adrenal cells for stable, long-term
basal hormone release as well as the response to pituitary adre-
nocorticotropic hormone (ACTH) and hypothalamic luteinizing
hormone-releasing hormone (LHRH) agonist, [D-Trp6]LHRH. The
enBACs were transplanted into adrenalectomized, immunodefi-
cient, and immunocompetent rats. Animals received enBACs intra-
peritoneally, under the kidney capsule (free cells or cells encapsulated
in alginate slabs) or s.c. enclosed in oxygenating and immunoisolating
βAir devices. Graft function was confirmed by the presence of cortisol
in the plasma of rats. Both types of grafted encapsulated cells,
explanted after 21–25 d, preserved their morphology and functional
response to ACTH stimulation. In conclusion, transplantation of a bio-
artificial adrenal with xenogeneic cells may be a treatment option for
patients with adrenocortical insufficiency and other stress-related dis-
orders. Furthermore, this model provides a microenvironment that
ensures 3D cell–cell interactions as a unique tool to investigate new
insights into cell biology, differentiation, tissue organization, and
homeostasis.
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Adrenal insufficiency is the failure of adrenocortical cells toproduce adequate amounts of glucocorticoids and/or min-
eralocorticoids. These steroid hormones play a central role in the
body’s homeostasis of energy, salt, and fluid; thus, adrenal in-
sufficiency is a potentially life-threatening condition. The most
relevant causes of adrenal insufficiency are autoimmune dis-
orders (up to 80%); infectious diseases; hereditary factors;
traumatic, metabolic, or neoplastic conditions; or surgical bi-
lateral adrenalectomy, sometimes due to a compulsory thera-
peutic strategy in the treatment of adrenal tumors or congenital
adrenal hyperplasia (CAH).
CAH due to 21-hydroxylase deficiency is the most common
form of inherited adrenal insufficiency, presenting with clinical
symptoms of neuroendocrine perturbations, virilization, and
metabolic diseases in later life. Patients may suffer from hypo-
tensive crises, hypoglycemia, acne, and infertility (1, 2). Current
options of treatment consisting of replacement therapy with
glucocorticoids, mineralocorticoids, and/or androgens can re-
verse the symptoms only partially, exhibit the unpleasant side
effects of inappropriate glucocorticoid substitution, and leave
the patients without the diurnal rhythm of glucocorticoid release.
Furthermore, adrenomedullary functions, including catechol-
amine and neuropeptide secretion, also are disrupted (2), which
correlates with cardiovascular risks, hypoglycemia, and physical
disability in these patients (1, 3).
Adrenal gland transplantation could and would be a desirable
therapeutic alternative for these patients if it was available and
practical (4). Transplanted organs restore and maintain normal
hormonal levels, adequately respond to functional demands, and
regulate steroid production in response to endogenous and ex-
ogenous stimulation, including the circadian rhythm of hormone
secretion. However, the application of this strategy is currently
extremely limited due to the lack of human donor organs, the
surgical difficulties of adrenal transplantation, and the required
chronic immunosuppression.
For the correction of adrenocortical insufficiency, transplan-
tation of whole adrenal glands might not be mandatory and the
transplantation of isolated adrenal cells may be sufficient. An
additional advantage of transplantation using isolated cells is
the availability of various immunoisolating materials and methods
for immune protection of such transplants. Application of these
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materials not only allows avoidance of chronic immunosuppres-
sion but also allows the transplantation of xenogeneic cells (5, 6).
Sodium alginate is one of the clinically approved immuno-
isolating biopolymers; it has already been widely used in a variety
of biomedical applications (5–10). Alginates have several unique
structural and chemical parameters, appropriate not only for
immune isolation but also for the creation of 3D cellular scaf-
folds that allow artificial organs to function long term in vitro
and in vivo (7, 8, 11). The potential of xenogeneic adrenocortical
cells to replace adrenal gland function has already been tested in
animal models but requires acquisition of immunodeficiency (12,
13). Alginate encapsulation may protect xenogeneic adrenocor-
tical cells from destruction by immunological processes (6). Al-
ternatively, similar to pancreatic islets (9, 14), adrenocortical
cells can be transplanted within special oxygenating and immu-
noisolating devices, thus reducing the risk of an immunological
host versus graft response.
Creating a long-lasting, immune-isolated, and functional bio-
artificial adrenal was the main aim of this research. The objectives
of our work included testing of primary bovine adrenocortical
cells (BACs) as a potential source of cells, defining optimal con-
ditions, and long-term monitoring. Because adrenocortical cells
also express receptors for luteinizing hormone-releasing hormone
(LHRH), the effect of the LHRH agonist [D-Trp6]LHRH on
adrenocortical steroidogenesis in encapsulated BACs (enBACs)
was tested. We characterized bioartificial adrenals in vivo and
investigated their functionality and efficacy after implantation into
bilaterally adrenalectomized rats.
Results
Long-Term Characterization of Functionality and Viability of Primary
BACs. The function of isolated adrenocortical cells was analyzed
by measuring basal and adrenocorticotropic hormone (ACTH)-
stimulated (3 ng/mL) production of cortisol (Fig. 1A). We found
that functional dynamics of BACs consisted of two phases. The
first phase (days 1–6) was characterized by high levels of basal
and stimulated production of cortisol, reaching a maximum on
days 4–6. During this phase, the stimulation index, reflecting the
functional potential of BACs, reached its maximum. Further-
more, BrdU incorporation showed a 3.5-fold increase in cell pro-
liferation on day 6 compared with day 1. During the second phase,
a decline of functional activity of BACs was observed, especially in
the response to ACTH, resulting in a functional degradation with
a dramatic reduction of the basal cortisol release and a total loss of
the ACTH-stimulated secretion of cortisol after 11 d in culture.
Increased functional activity of BACs during the first phase
was also associated with a significant elevation of the oxygen
consumption rate (OCR), characterizing the metabolic state of
the cells (Fig. 1B). On day 4, the peak of functional activity of
cells, levels of OCR reached almost twice the value of 1-d-old cell
cultures (1.88 ± 0.21 × 10−15 vs. 1.00 ± 0.06 × 10−15 mol·min−1·cell−1,
P < 0.05). The amount of oxygen consumed by BACs is com-
parable to other cell types tested in our laboratory—for example,
rat β cells (2.96 ± 0.87 × 10−15 mol·min−1·cell−1) (14). ACTH
stimulation led to increased oxygen consumption compared with
nonstimulated cells, which, however, did not reach statistical
significance.
The second phase, characterized by a decrease of functional
activity of BACs, was closely associated with a significant in-
crease in caspase activity and apoptosis. In parallel with the
observed decrease in steroidogenic activity, caspase activity
progressively increased more than twofold (Fig. 1C). Complete
loss of functionality of BACs was observed on day 14–20, which
corresponds to previously published data (15). Morphologically,
this process was accompanied by the increased number of dead
cells and the overgrowth with fibroblast-like cells (Fig. 1D).
Three-Dimensional Cultures of Adrenal Cells by Encapsulation in
Alginate. To optimize the survival and function of adrenal cells,
they were encapsulated in alginate. To identify the optimal time
point for cell survival and function for BAC encapsulation, we
encapsulated BACs in alginate on day 1 and on day 7 after their
isolation from intact organs. The highest functional peak of
cortisol (143 ± 31 ng/mL for basal and 298 ± 109 ng/mL for
stimulated cortisol) was observed with the cells that were en-
capsulated on day 1 after isolation. With those cells, encapsu-
lated on day 7, maximal basal cortisol reached 108 ± 18 ng/mL,
and stimulated cortisol 259 ± 43 ng/mL. After a 1-month culti-
vation, both groups of enBACs released identical cortisol levels
(basal levels of 23 ± 3.4 ng/mL for the day 1 group and 20 ± 11.6
ng/mL for the day 7 group and ACTH-stimulated levels of 103 ±
31 ng/mL for the day 1 group and 108 ± 32 ng/mL for the day 7
group). Thus, for the creation of bioartificial adrenals, cells can
be encapsulated any time within the first 7 d after isolation.
In addition to the time in culture, the density of the cells en-
capsulated in alginate strongly affected the functionality of
BACs. The optimal density was 14,000–20,000 cells per 1 μL
alginate (Fig. 2A). Higher cell densities reduced BAC activity as
a function of cell number. Alginate itself creates a diffusion
barrier that plays a key role in nutrient and oxygen availability.
When the thickness of the slab exceeded 500 μm (maximum
1,000 μm), cell response upon stimulation with ACTH was
weaker in comparison with thinner slabs (200–500 μm). Al-
though basal cortisol was 37 ± 12 ng/mL for both groups, stim-
ulation with ACTH resulted in the release of 140 ± 88 ng/mL
cortisol from thicker and 373 ± 62 ng/mL cortisol from thinner
slabs (n = 6), respectively.
Interactions between different cell types within the adrenal
also play an important role in the regulation of adrenocortical
function (16). The influence of adrenomedullary cells on the
function of adrenocortical cells is reflected in culture conditions;
the steroidogenic activity of adrenocortical cells increased 10-
fold by coculture with chromaffin cells (17). We assessed the
impact of chromaffin cells on BAC cortisol production and via-
bility in 3D cell culture conditions. For this purpose, chromaffin
cells at a ratio of 1:5 were added to the standard number of cortical
Fig. 1. Long-term characterization of functionality and viability of primary
BACs. (A) Functional activity of free cultured cells. Basal and ACTH- (3 ng/mL)
stimulated cortisol level (n = 15 for each value,*P < 0.05 basal vs. ACTH-
stimulated cortisol). (B) OCR of free cultured cells (n = 4 for each value, *P <
0.05). (C) Caspase activity, reflecting intensity of apoptosis in BAC culture
(n = 3 for each value, **P < 0.01). (D) Degradation of BAC culture on day 14
(FDA/PI staining) with increased amount of dead cells (a) and areas domi-
nated by fibroblast-like cells (b).
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cells. In the control group, only cortical cells were encapsulated.
Encapsulation of chromaffin cells with adrenocortical cells had no
influence on cortisol release, however a significant increase in BAC
viability was observed (Fig. 2B; P < 0.05).
Validation of Bioartificial Adrenals: Long-Term Monitoring of Function-
ality of BACs Encapsulated in Alginate in Vitro. Dynamics of the func-
tional activity of adrenocortical cells in 3D matrix over 70 d are
presented in Fig. 2C. In the first days of culture, cortisol release
from enBACs increased, with a peak on day 14 followed by a
sharp decrease. In contrast to BACs in monolayer culture,
functional activity of enBACs was preserved beyond 14–20 d in
culture. enBACs had a long phase of stable cortisol production,
which continued until the end of the observation period of 70 d.
Moreover, unlike cells in free culture, enBACs did not lose their
ability to respond to ACTH stimulation (Fig. 2C).
Another feature of enBACs was a cyclic pattern of cortisol
release (Fig. 2C). Following the end of the first cycle at day 20,
a second cycle started with a statistically significant increase and
decrease in cortisol levels. Functional cycles of enBACs repeated,
albeit with a slightly lower amplitude during the whole observation
period (70 d). The accuracy of cycling was statistically confirmed
by a Wilcoxon signed-rank test for related samples (P < 0.05). The
frequency of cycling was ∼20 d.
Impact of LHRH Agonist [D-Trp6]LHRH and Retinoic Acid on enBACs.
Adrenocortical cells express receptors for both LHRH and ret-
inoic acid (18, 19). The LHRH agonist [D-Trp6]LHRH is clini-
cally approved for the treatment of hormone-dependent cancers,
predominantly prostate cancer. Over the course of treatment,
[D-Trp6]LHRH causes a surge of testosterone release at the be-
ginning and then a reduction to levels similar to postcastration
levels approximately 4 wk after injection (20, 21). Retinoic acid is
involved in the regulation of steroidogenesis, and its use signifi-
cantly reduces cortisol secretion (19). [D-Trp6]LHRH and reti-
noic acid both influenced basal (Fig. 2D) and ACTH-stimulated
cortisol secretion from enBACs. Similar to its effect on testos-
terone-producing cells, [D-Trp6]LHRH significantly increased
basal cortisol production by 74% on day 4 after the beginning of
treatment. Stimulated adrenocortical cells are characterized by
specific subcellular features reflecting steroidogenesis, such as an
increased amount of inner mitochondrial membrane and endo-
plasmic reticulum (22). Similarly, enBACs treated with [D-Trp6]
LHRH presented with ample smooth and rough endoplasmic
reticulum and mitochondria with a densely packed inner mito-
chondrial membrane (Fig. 2 E and F). In contrast to [D-Trp6]
LHRH, treating the cells with retinoic acid for 6 d significantly
decreases basal cortisol secretion levels to 26% of control levels.
Forty-eight hours following discontinuation of retinoic acid and
[D-Trp6]LHRH application, cortisol release had returned to basal
levels with no difference compared with the control group.
In Vivo Application of Bioartificial Adrenal for Glucocorticoid Replace-
ment Therapy. In vivo testing was performed in adrenalectomized
rats (n = 15)—4 immunodeficient and 11 normal immunocom-
petent animals.
Efficiency of enBACs was first assessed by transplantation into
athymic, adrenalectomized Rowett Nude (RNU) rats. The con-
trol group of animals received 1 × 107 free adrenocortical cells,
injected under the kidney capsule. The experimental group re-
ceived the identical number of cells encapsulated in alginate
enBACs, placed in the subcapsular space of the kidney. The
animals underwent clinical observation for 25 d. Every second
day, the functionality of the graft was determined by measuring
cortisol levels in blood samples taken from the tail tip. Control
animals, after an initial weight loss (6–8%) during the first 5 d after
surgery, showed a stable weight gain, reaching 110–115% of the
initial weight by the end of the observation period. The animals
were lively; no abnormal behavior was observed. Postoperatively,
blood cortisol levels increased 6–10 times on day 7 compared with
the reference period 2 and 4 d postoperation (3,857 ± 1,057 pg/mL
vs. 209 ± 70 pg/mL). Dynamics of cortisol concentration displayed
a tendency to decrease after reaching a peak on day 11. Statistically
this trend was characterized by a low coefficient of negative
Spearman’s rank correlation between length of transplantation and
cortisol levels (r = –0.32, P > 0.05). RNU rats with implanted
enBACs presented with a better postsurgical recovery and weight
gain than those with transplanted free cells. They reached their
initial weight 7 d after surgery, whereas rats with transplanted free
cells had regained their initial weight only by the 13th day. These
positive clinical differences in the postoperative status were also
associated with higher blood cortisol levels. Average cortisol
concentrations in animals with enBACs were 9,195 ± 2,053
pg/mL, 2.5 times higher than the levels of the control group.
Remarkably, in contrast to the downward trend of cortisol levels
in the group that received free cell transplantation, blood cortisol
levels in animals with implanted enBACs demonstrated a pro-
gressive increase during the entire observation period (r = +0.93,
P < 0.05), reaching 16 ng/mL on day 25 postimplantation (Fig.
3A). At the explantation of enBACs, a thin membrane of con-
nective tissue surrounding the slabs, heavily penetrated by blood
vessels, was observed (Fig. 3B). Explanted enBACs preserved
functional, viable adrenocortical cells (Fig. 3C), as proven by the
Fig. 2. Maintenance and optimization of adrenal cell survival and function
by encapsulation in alginate. (A) Optimal density for cell survival and func-
tion in alginate (n = 3 for each value). (B) Encapsulation of chromaffin cells
with cortical cells improves cell viability after 21 d of cultivation; data are
shown as percentage of viable cells from pure cortical cultures (n = 6 for
each value, **P < 0.001). (C) Long-term monitoring of enBAC functionality.
Cortisol levels [basal and ACTH-stimulated (3 ng/mL); n = 18 for each value].
(D) Effect of LHRH agonist [D-Trp6]LHRH and retinoic acid on basal cortisol
secretion. Data are shown as percent of control (n = 6 for all groups, *P <
0.05 compound vs. control). (E and F) Electron micrographs of enBACs
treated with [D-Trp6]LHRH with subcellular features of stimulated cells such
as ample rough endoplasmic reticulum, smooth endoplasmic reticulum, and
mitochondria with a densely packed inner mitochondrial membrane.
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release of 95 ng/mL cortisol per 1 × 107 cells after 2 h of con-
tinuous stimulation with ACTH (3 ng/mL).
To test the immunoprotective properties of encapsulation
compared with immunoisolating devices, enBACs were trans-
planted into immunocompetent animals (Wistar rats) without the
use of immunosuppressive drugs. Before starting the experiments,
basal corticosterone levels of the rats were 93 ± 41 ng/mL and
ACTH-stimulated levels 167 ± 49 ng/mL. After adrenalectomy,
the animals were divided into three groups. The first group of ani-
mals (n = 4) received no treatment and was used as a control. The
second group of rats received 1 × 107 enBACs i.p. (n = 4). The third
group received 1 × 107 cells implanted s.c. in oxygenated immu-
noisolating devices (n = 3). The survival curves for the first and
second group are presented in Fig. 4A. All animals without BAC
transplantation (control) died within 12 d after adrenalectomy.
These rats exhibited severe signs of adrenal insufficiency, with
a progressive weight loss (Fig. 4B), decreased motor activity, and
apathy. All animals receiving i.p. enBAC implants survived until the
end of the observation period (21 d). Their body weight increased
after a slight decline during the first 3 d (Fig. 4B). The rats were
active without symptoms of apathy. These positive clinical signs
were associated with high levels of basal and ACTH-stimulated
blood cortisol (Fig. 4C) without a concomitant recurrence of rel-
evant endogenous corticosterone levels (31–371 pg/mL). Average
cortisol concentrations increased to 2,741 ± 723 pg/mL (n = 24, six
samples from four animals). In addition, blood cortisol levels in
these rats increased significantly by 2–3-fold, in response to ACTH
stimulation, to 6,656 ± 1,295 pg/mL (P < 0.05). During explanta-
tion of enBACs on day 21, we found the slabs to be attached to the
peritoneum (Fig. 4D); viability staining [fluorescein diacetate/
propidium iodide (FDA/PI)] showed a high number of viable cells
(more than 90% of the initial number). Preservation of cell
function was confirmed by its ability to respond to stimulation with
ACTH by releasing 76.4 ± 20 ng/mL of cortisol per 1 × 107 cells
after 2 h of continuous stimulation with ACTH (3 ng/mL, n = 8).
Implantation of xenogeneic cells is associated with the risk of
immune sensitization and graft rejection. Placing of xenogeneic
material inside isolating devices provides additional protection
from graft–host interaction. In this study, we used oxygenated
immune-isolating devices, which have already undergone suc-
cessful testing in the transplantation of islets of Langerhans with
the goal to treat diabetic patients (5, 7, 10, 14, 23). Here, we
performed a pilot study to determine the possibility of adapting
this device for transplantation of enBACs. For this purpose,
enBACs in devices were implanted s.c. in the dorsal area in three
Wistar rats. The animals survived until the end of the experiment,
but weight loss lasted longer and was more severe compared with
the animals, transplanted i.p. with slab (Fig. 4B). The rats were
less active and less mobile. These clinical differences were prob-
ably caused by the inconvenience related to the device size as
well as the stress associated with the implementation of device
oxygenation. Blood cortisol levels (1,251 ± 232 pg/mL) were
slightly lower than in the animals with i.p. enBAC implants (Fig.
4C). To a large extent, this can be explained by the presence of the
immunoisolating double polytetrafluoroethylene (PTFE) mem-
brane, which might form a diffusion barrier to cortisol. However,
the rats responded to ACTH stimulation by a significant elevation
in blood cortisol (Fig. 4C). Explanted enBACs preserved a high
viability (Fig. 4E) and functionality as confirmed by the production
of 114 ± 28 ng/mL of cortisol per 1 × 107 cells after 2 h of con-
tinuous stimulation with ACTH (3 ng/mL, n = 3).
Discussion
Primary cultures of BACs have been a widely used model to
study different aspects of adrenal function in vitro and in vivo
(16, 24). Moreover, bovine adrenal can also be a cell source for
xenogeneic transplantation in the treatment of adrenocortical
deficiency. Here we show that a bioartificial adrenal gland can be
created from BACs by culturing them in a 3D alginate matrix.
This matrix protected transplanted cells from the host immune
system in immunocompentent rats; the transplanted cells were
active and rescued the animals from the lethal effects of adre-
nalectomy by restoring normal glucocorticoid levels.
The prerequisite to create an artificial adrenal is the capacity
for long-term culture of adrenocortical cells and their ability to
produce adrenocortical steroids that are secreted in a normal
manner upon specific stimulation. In the present study, BACs in
long-term primary monolayer culture (free BACs) underwent
a process of phenotypic changes leading to loss of steroidogenic
activity. As previously shown, this process is due to a loss of ex-
pression of steroid hydroxylases during prolonged cellular culture
(15). Furthermore, culture of free BACs was characterized by
increased apoptosis, cell degradation, and a limitation of life span.
A number of studies indicate the importance of 3D structure
for cell–cell interactions, particularly for encapsulation in alginate
(6, 11). Our in vitro data show that encapsulation in alginate,
indeed, provides adrenocortical cells with 3D culture conditions,
which prevent the loss of steroidogenic activity. The functional
capacity significantly exceeded that of traditional 2D cell culture.
This discovered ability of enBACs for long-term function in vitro as
well as the potential for regeneration or restoration of impaired
function suggests the suitability of a 3D alginate matrix for the
creation of a bioartificial adrenal gland.
Such an artificial adrenal can open new medical horizons for
studying the complex intraadrenal cell–cell interactions and
would implement effective investigations and primary screenings
of pharmacological agents. Here we show that the LHRH agonist
[D-Trp6]LHRH significantly increased basal and ACTH-stimu-
lated cortisol secretion from enBACs, indicating its potential in
activating adrenocortical steroidogenesis in this artificial gland. The
clinically approved drug [D-Trp6]LHRH thus might deliver the
potential to improve steroidogenesis in transplanted adrenocortical
Fig. 3. Application of bioartificial adrenal for glucocorticoid replacement therapy in vivo. Trial was on RNU rats. (A) Linear trendline of blood cortisol.
(B) Highly vascularized slab (a) before and (b) after explantation. (C) High cell viability after explantation (FDA/PI staining; green, live; red, dead).
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cells. Such an artificial adrenal might also allow the in vitro study of
adrenocortical stem and progenitor cells that, so far, were impos-
sible to isolate and culture, probably due to the inability to recon-
struct the 3D in vivo environment in a culture dish (25). Most
importantly, the creation of an artificial adrenocortical tissue with
long-term stability opens the possibility for the transplantation of
these cells with the goal of treating patients with adrenocortical in-
sufficiency or adrenal hyperplasia due to 21-hydroxylase deficiency.
In a first set of experiments, we tested the potential of trans-
planted enBACs in adrenalectomized athymic, T-cell–deficient
nude rats (RNU rats) to replace the host’s glucocorticoid pro-
duction. In accordance with our in vitro data indicating an in-
creased functional activity and longevity of enBACs compared
with free BACs, rats that received enBAC transplants presented
with faster recovery, more rapid weight gain, and higher blood
cortisol levels compared with adrenalectomized rats receiving
free cells. In addition to the supportive function of the alginate
matrix in preserving the steroidogenic function of the cells, the
rich capillary network formed around the transplanted slabs
might play an important role in preserving functional viability
of the cells. The development of vascularization at the site of
transplantation is important for the survival, growth, and func-
tion of transplanted tissue; it provides access to nutrients and is
associated with stable levels of blood cortisol (26).
In a second set of experiments, we then addressed the question
of whether encapsulation of BACs isolates and protects the cells
from the immune system of the host. We compared the trans-
plantation of enBACs alone into immune-competent Wistar rats
with the transplantation of BACs in an immune-isolating device
that has already been used successfully to transplant pancreatic
islets of Langerhans without the use of immunosuppressive drugs.
This device has been used both in animal models (5, 10, 14, 23) as
well as in a patient suffering from diabetes type 1 (7). enBACs in
all groups of adrenalectomized animals were functional, replaced
corticosteroids, and rescued the animals from the lethal effect
of adrenalectomy.
Transplanted enBACs were isolated from the recipient’s im-
mune system, whereas low-molecular-weight substances (nutrients,
electrolytes, oxygen, and bioactive secretion products) freely diffuse
through the micropores of the alginate (6). Thus, transplanted
enBACs maintained their functional activity and viability through-
out the observation period without the use of immunosuppression.
Daily external oxygenation of the device helped to maintain cellular
viability and endocrine function of the bioartificial adrenal as pre-
viously demonstrated in our diabetes models and patients (5, 7).
After explantation of enBACs, a light transparent membrane with a
small amount of cellular elements and a rich network of capillary
vessels was found around the slabs. Absence of fibrosis around
enBACs in our experiments can be understood to mean that the
main secretory product of BACs is cortisol, which has well-known
fibroblast-suppressive and immunosuppressive properties (27). The
formation of such an abundant capillary network around the arti-
ficial adrenal might be stimulated by the recently discovered unique
ability of steroid-producing cells to release a specific angiogenic
factor, the endocrine-gland–derived vascular endothelial growth
factor (28). The ability of enBACs to suppress fibrosis, on one hand,
and to stimulate development of a capillary microenvironment, on
the other hand, opens new prospects for the use of cortisol-pro-
ducing cells not only in the treatment of adrenal insufficiency but
also for combined transplantations, for example, together with islets
of Langerhans.
Current treatment options for adrenal insufficiency or CAH
are limited to glucocorticoid, mineralocorticoid, and DHEA
replacement. Glucocorticoids are secreted following a circadian
rhythm with the highest peak in the morning and the nadir at
night. This circadian rhythm is complicated to replicate by current
enteral/parenteral replacement therapies with synthetic gluco-
corticoids, and patients thereby suffer from a poor quality of life
and increased mortality (29). Even more challenging is the treatment
of adrenal insufficiency in childhood, where daily doses must be
additionally adjusted to growth.
Fig. 4. Application of bioartificial adrenal for glucocorticoid replacement therapy in vivo. Trial was on Wistar rats. (A) Survival curve of Wistar rats. (B) Body
weight monitoring of Wistar rats [n = 4 for adrenalectomized (ADX) and animals that received enBACs (Slabs) and n = 3 for the rats that received an
implanted device]. (C) Blood cortisol of Wistar rats (from four ADX animals; n = 15 for basal cortisol and n = 4 for ACTH-stimulated), with slabs (n = 24 for
basal cortisol and n = 12 for ACTH-stimulated—from four animals), and of animals with implanted devices (n = 18 for basal and n = 9 for stimulated blood
cortisol from three rats; *P < 0.05). (D) The i.p. transplanted slab attached to peritoneum at explantation. (E) Live/dead (FDA/PI) staining of explanted enBACs
from device (green, live cells; red, dead cells).
Balyura et al. PNAS | February 24, 2015 | vol. 112 | no. 8 | 2531
M
ED
IC
A
L
SC
IE
N
CE
S
Adrenal insufficiency due to CAH is mostly diagnosed in early
childhood. Patients with CAH have, in addition to the deficiency of
glucocorticoids and mineralocorticoids in adolescence, an increased
risk of hyperandrogenism and thus require higher doses of gluco-
corticoids, which often leads to loss of height and shortened adult
stature (30). Thus, adrenal cell transplantation and the restoration of
normalized HPA-axis function would be a particularly beneficial
option for these patients. Furthermore, it may prevent adrenal crisis.
The results of the present study indicate that BACs encapsu-
lated in alginate are suitable for replacement therapy of adre-
nocortical insufficiency not only by their direct i.p. administration
to a recipient but also when implanted in a special oxygenated
immunoisolating device. Direct transplantation of immune-isolated
xenogeneic cells in biomatrices undoubtedly has great prospects.
However, the widespread clinical application of this trans-
plantation method is currently limited by inevitable risks from
a direct contact of the host’s immune system with the xenogeneic
material. Biomatrix degradation may potentially lead to the es-
cape of breakdown products of the matrix and the development
of sensitization to the newly immunologically exposed cells. In
this regard, along with the creation of artificial endocrine organs
on the basis of encapsulated primary xenogeneic cells in 3D
scaffolds, their additional protection within oxygenated immu-
noisolating devices is a further promising approach to the re-
generative therapy of patients with adrenal insufficiency or other
polyglandular autoimmune insufficiencies.
Materials and Methods
The complete description of the methods is in SI Text.
Cell Preparation and Culture. BACs and chromaffin cells were isolated from
bovine adrenals of freshly slaughtered 1–3-y-old cattle by collagenase di-
gestion, as previously described (17, 31, 32).
Cell Encapsulation. Pelleted BACs were gently mixed with 3.5% (wt/vol) sterile
high guluronic acid (HG) alginate, dissolved in Custodiol-HTK solution (H.S.
Pharma). The alginate–cell mixture was then placed either on a glass (for
slabs) or spread in the cell compartment of the chamber device (10). Then
alginate was cross-linked by applying flat Sintered glass (Pyrex), saturated
with 70 mM strontium chloride plus 20 mM Hepes. The thickness of alginate/
cell slab was 550 μm.
Experiments with the LHRH Agonist [D-Trp6]LHRH and Retinoic Acid. The LHRH
agonist [D-Trp6]LHRH, dissolved in DMSO, was used at 10−6 M/L; retinoic acid,
dissolved in ethanol, was applied at a concentration of 5 μM/L.
In Vivo Sudies. Female RNU (8 wk old) and female Wistar rats (200 g) were
obtained from Charles River Laboratory.
Adrenalectomy and Implantation. Bilateral adrenalectomy was performed simul-
taneously with the cell transplantation procedure. For naked cell transplantation,
5 × 106 of bovine adrenocortical cells were infused into a pouch formed under
the capsule of each kidney. For encapsulated cell transplantation, two identical
slabs were implanted, one underneath each kidney capsule. For i.p. trans-
plantation in adrenalectomized Wistar rats, two slabs, containing 5 × 106 cells
each, were carefully placed into the retroperitoneal space. Macrochambers were
placed under the dorsal skin. An oxygen-enriched gas mixture (60% oxygen,
35% nitrogen, 5% CO2) was used for daily “refueling” of the gas module.
Ethics Statement. All animal experiments were performed in strict accordance
with animal protocols approved by the ethical and research board of the
Regierungspräsidium Dresden.
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